Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Feb 27, 2024
Episode
206
Soundcloud
Share
ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers, but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust Florez and guests Dr. Christine Lovly from Vanderbilt University and Yvonne Diaz from Oncogene Cancer Research discuss how an ALK-positive diagnosis is made and what therapies are currently available to treat it.
Guest
Christine Lovly
MD
Associate Professor of Medicine, Division of Hematology-Oncology
Vanderbilt University Medical Center
Vanderbilt Ingram Cancer Center
Yvonne Diaz
Patient Advocate
Co-Founder, Oncogene Cancer Research
